| pubmed-article:11063837 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11063837 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:11063837 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11063837 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:11063837 | lifeskim:mentions | umls-concept:C0015980 | lld:lifeskim |
| pubmed-article:11063837 | lifeskim:mentions | umls-concept:C0209606 | lld:lifeskim |
| pubmed-article:11063837 | lifeskim:mentions | umls-concept:C1416487 | lld:lifeskim |
| pubmed-article:11063837 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:11063837 | pubmed:dateCreated | 2000-12-1 | lld:pubmed |
| pubmed-article:11063837 | pubmed:abstractText | Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-beta (IFN-beta) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-beta1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-beta treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ 'memory' T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS. | lld:pubmed |
| pubmed-article:11063837 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11063837 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063837 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11063837 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11063837 | pubmed:issn | 0165-5728 | lld:pubmed |
| pubmed-article:11063837 | pubmed:author | pubmed-author:McFarlandH... | lld:pubmed |
| pubmed-article:11063837 | pubmed:author | pubmed-author:LeistTT | lld:pubmed |
| pubmed-article:11063837 | pubmed:author | pubmed-author:MuraroP APA | lld:pubmed |
| pubmed-article:11063837 | pubmed:author | pubmed-author:BielekovaBB | lld:pubmed |
| pubmed-article:11063837 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11063837 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11063837 | pubmed:volume | 111 | lld:pubmed |
| pubmed-article:11063837 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11063837 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11063837 | pubmed:pagination | 186-94 | lld:pubmed |
| pubmed-article:11063837 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:meshHeading | pubmed-meshheading:11063837... | lld:pubmed |
| pubmed-article:11063837 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11063837 | pubmed:articleTitle | VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. | lld:pubmed |
| pubmed-article:11063837 | pubmed:affiliation | Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive MSC1400, 20892-1400, Bethesda, MD, USA. pmuraro@umich.it | lld:pubmed |
| pubmed-article:11063837 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11063837 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063837 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063837 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063837 | lld:pubmed |
